Humoral and Cellular Responses After a Third Dose of SARS-CoV-2 BNT162b2 Vaccine in Patients with Lymphoid Malignancies

Overview

Journal Nat Commun

Specialty Biology

Date 2022 Feb 15

PMID 35165284

Authors

Daniel Re

Barbara Seitz-Polski

Vesna Brglez

Michel Carles

Daisy Graca

Sylvia Benzaken

Stephane Liguori

Khaled Zahreddine

Margaux Delforge

Beatrice Bailly-Maitre

Benjamin Verriere

Emmanuel Chamorey

Jerome Barriere

Affiliations

Soon will be listed here.

Abstract

Patients with hematological malignancies have impaired immune response after two doses of BNT162b2 (Pfizer/BioNTech) vaccine against SARS-CoV-2. Here, in this observational study (registration number HDH F20210324145532), we measure SARS-CoV-2 anti-Spike antibodies, neutralizing antibodies and T-cell responses after immune stimulation with a third dose (D3) of the same vaccine in patients with chronic lymphocytic leukemia (n = 13), B cell non-Hodgkin lymphoma (n = 14), and multiple myeloma (n = 16)). No unexpected novel side effects are reported. Among 25 patients with positive anti-S titers before D3, 23 (92%) patients increase their anti-S and neutralizing antibody titer after D3. All 18 (42%) initially seronegative patients remain negative. D3 increases the median IFN-γ secretion in the whole cohort and induces IFN-γ secretion in a fraction of seronegative patients. Our data thus support the use of a third vaccine dose amongst patients with lymphoid malignancies, even though some of them will still have vaccine failure.

Citing Articles

BNT162b2 mRNA vaccination affects the gut microbiome composition of patients with follicular lymphoma and chronic lymphocytic leukemia.

Chiarenza A, Aluisio G, Parrinello N, Marino S, Corsale A, Privitera G Biomark Res. 2025; 13(1):25.

PMID: 39930533 PMC: 11812150. DOI: 10.1186/s40364-025-00734-w.

SARS-CoV-2-Specific T Lymphocytes Analysis in mRNA-Vaccinated Patients with B-Cell Lymphoid Malignancies on Active Treatment.

Garcia Ramirez P, Callejas Charavia M, Oliva Martin R, Gomez La Hoz A, Ortega M, Garcia Suarez J Vaccines (Basel). 2024; 12(9).

PMID: 39339993 PMC: 11435597. DOI: 10.3390/vaccines12090961.

Kinetics of humoral and cellular immune responses 5 months post-COVID-19 booster dose by immune response groups at the peak immunity phase: An observational historical cohort study using the Fukushima vaccination community survey.

Kobashi Y, Kawamura T, Shimazu Y, Kaneko Y, Nishikawa Y, Sugiyama A Vaccine X. 2024; 20:100553.

PMID: 39309610 PMC: 11416657. DOI: 10.1016/j.jvacx.2024.100553.

Efficacy of Combination of Antiviral Therapy With Neutralizing Monoclonal Antibodies for Recurrent Persistent SARS-CoV-2 Pneumonia in Patients With Lymphoma.

Gai X, Sun X, Liu B, Yan W, Sheng Z, Zhou Q Biomed Res Int. 2024; 2024:8182887.

PMID: 39140001 PMC: 11321881. DOI: 10.1155/2024/8182887.

Examining the immunological responses to COVID-19 vaccination in multiple myeloma patients: a systematic review and meta-analysis.

Harandi H, Fallahtafti P, Karimi A, Hashemi S, Mahalleh M, Ashouri M BMC Geriatr. 2024; 24(1):411.

PMID: 38720296 PMC: 11080142. DOI: 10.1186/s12877-024-05006-0.

References

Palich R, Veyri M, Vozy A, Marot S, Gligorov J, Benderra M . High seroconversion rate but low antibody titers after two injections of BNT162b2 (Pfizer-BioNTech) vaccine in patients treated with chemotherapy for solid cancers. Ann Oncol. 2021; 32(10):1294-1295. PMC: 8217700. DOI: 10.1016/j.annonc.2021.06.018. View

Martinez-Gallo M, Esperalba J, Pujol-Borrell R, Sanda V, Arrese-Munoz I, Fernandez-Naval C . Commercialized kits to assess T-cell responses against SARS-CoV-2 S peptides. A pilot study in health care workers. Med Clin (Barc). 2021; 159(3):116-123. PMC: 8463390. DOI: 10.1016/j.medcli.2021.09.013. View

Bange E, Han N, Wileyto P, Kim J, Gouma S, Robinson J . CD8 T cells contribute to survival in patients with COVID-19 and hematologic cancer. Nat Med. 2021; 27(7):1280-1289. PMC: 8291091. DOI: 10.1038/s41591-021-01386-7. View

Kamar N, Abravanel F, Marion O, Couat C, Izopet J, Del Bello A . Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients. N Engl J Med. 2021; 385(7):661-662. PMC: 8262620. DOI: 10.1056/NEJMc2108861. View

Re D, Barriere J, Chamorey E, Delforge M, Gastaud L, Petit E . Low rate of seroconversion after mRNA anti-SARS-CoV-2 vaccination in patients with hematological malignancies. Leuk Lymphoma. 2021; 62(13):3308-3310. DOI: 10.1080/10428194.2021.1957877. View

Barriere J, Chamorey E, Adjtoutah Z, Castelnau O, Mahamat A, Marco S . Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumors. Ann Oncol. 2021; 32(8):1053-1055. PMC: 8080507. DOI: 10.1016/j.annonc.2021.04.019. View

Apostolidis S, Kakara M, Painter M, Goel R, Mathew D, Lenzi K . Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. Nat Med. 2021; 27(11):1990-2001. PMC: 8604727. DOI: 10.1038/s41591-021-01507-2. View

Schmidt T, Klemis V, Schub D, Mihm J, Hielscher F, Marx S . Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination. Nat Med. 2021; 27(9):1530-1535. PMC: 8440177. DOI: 10.1038/s41591-021-01464-w. View

Planas D, Veyer D, Baidaliuk A, Staropoli I, Guivel-Benhassine F, Rajah M . Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature. 2021; 596(7871):276-280. DOI: 10.1038/s41586-021-03777-9. View

10.

Wang Q, Berger N, Xu R . Analyses of Risk, Racial Disparity, and Outcomes Among US Patients With Cancer and COVID-19 Infection. JAMA Oncol. 2020; 7(2):220-227. PMC: 7729584. DOI: 10.1001/jamaoncol.2020.6178. View

11.

Woldemeskel B, Garliss C, Blankson J . SARS-CoV-2 mRNA vaccines induce broad CD4+ T cell responses that recognize SARS-CoV-2 variants and HCoV-NL63. J Clin Invest. 2021; 131(10). PMC: 8121504. DOI: 10.1172/JCI149335. View

12.

Herishanu Y, Avivi I, Aharon A, Shefer G, Levi S, Bronstein Y . Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood. 2021; 137(23):3165-3173. PMC: 8061088. DOI: 10.1182/blood.2021011568. View

13.

Dulery R, Lamure S, Delord M, Di Blasi R, Chauchet A, Hueso T . Prolonged in-hospital stay and higher mortality after Covid-19 among patients with non-Hodgkin lymphoma treated with B-cell depleting immunotherapy. Am J Hematol. 2021; 96(8):934-944. PMC: 8212109. DOI: 10.1002/ajh.26209. View

14.

Schiffner J, Backhaus I, Rimmele J, Schulz S, Mohlenkamp T, Klemens J . Long-Term Course of Humoral and Cellular Immune Responses in Outpatients After SARS-CoV-2 Infection. Front Public Health. 2021; 9:732787. PMC: 8502872. DOI: 10.3389/fpubh.2021.732787. View

15.

Mansi L, Spehner L, Daguindau E, Bouiller K, Almotlak H, Stein U . Study of the SARS-CoV-2-specific immune T-cell responses in COVID-19-positive cancer patients. Eur J Cancer. 2021; 150:1-9. PMC: 7997727. DOI: 10.1016/j.ejca.2021.03.033. View

16.

Grivas P, Khaki A, Wise-Draper T, French B, Hennessy C, Hsu C . Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium. Ann Oncol. 2021; 32(6):787-800. PMC: 7972830. DOI: 10.1016/j.annonc.2021.02.024. View

17.

Michot J, Hueso T, Ibrahimi N, Pommeret F, Willekens C, Colomba E . Severe COVID-19 in patients with hematological cancers presenting with viremia. Ann Oncol. 2021; 32(10):1297-1300. PMC: 8275471. DOI: 10.1016/j.annonc.2021.07.002. View

18.

Hall V, Ferreira V, Ku T, Ierullo M, Majchrzak-Kita B, Chaparro C . Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients. N Engl J Med. 2021; 385(13):1244-1246. PMC: 8385563. DOI: 10.1056/NEJMc2111462. View

19.

Benotmane I, Gautier G, Perrin P, Olagne J, Cognard N, Fafi-Kremer S . Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients With Minimal Serologic Response to 2 Doses. JAMA. 2021; . PMC: 8456389. DOI: 10.1001/jama.2021.12339. View

20.

Yamayoshi S, Yasuhara A, Ito M, Akasaka O, Nakamura M, Nakachi I . Antibody titers against SARS-CoV-2 decline, but do not disappear for several months. EClinicalMedicine. 2021; 32:100734. PMC: 7877219. DOI: 10.1016/j.eclinm.2021.100734. View